This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: F. Hoffmann-La Roche Ag. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Sabine Lang: Innovator in Combination Therapy
Introduction
Sabine Lang is a prominent inventor based in Schlieren, Switzerland. She has made significant contributions to the field of medical research, particularly in the area of combination therapies. Her innovative work has led to the development of a unique patent that addresses critical health challenges.
Latest Patents
Sabine Lang holds a patent titled "Combination Therapy with Targeted 4-1BB (CD137) Agonists/Anti-FAP Binding Domain and Anti-CEA/Anti-CD3 Bispecific Antibody." This patent represents a significant advancement in therapeutic strategies, showcasing her expertise and commitment to improving patient outcomes.
Career Highlights
Throughout her career, Sabine has been associated with F. Hoffmann-La Roche AG, a leading global healthcare company. Her role at Roche has allowed her to collaborate with some of the brightest minds in the industry, further enhancing her contributions to medical science.
Collaborations
Sabine has worked alongside talented colleagues, including Christina Claus and Claudia Ferrara Koller. These collaborations have fostered an environment of innovation and creativity, leading to groundbreaking advancements in their field.
Conclusion
Sabine Lang's work exemplifies the spirit of innovation in the medical field. Her dedication to developing effective therapies is evident in her patent and collaborations. She continues to be a valuable asset to the scientific community, driving progress in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile